-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Head-To-Head Analysis: Cardio Diagnostics (NASDAQ:CDIO) and Quotient (NASDAQ:QTNT)
Head-To-Head Analysis: Cardio Diagnostics (NASDAQ:CDIO) and Quotient (NASDAQ:QTNT)
Quotient (NASDAQ:QTNT – Get Rating) and Cardio Diagnostics (NASDAQ:CDIO – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability and earnings.
Valuation & Earnings
This table compares Quotient and Cardio Diagnostics' top-line revenue, earnings per share (EPS) and valuation.
Get Quotient alerts:Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Quotient | $38.51 million | 0.03 | -$125.13 million | ($53.21) | -0.01 |
Cardio Diagnostics | N/A | N/A | -$140,000.00 | N/A | N/A |
Cardio Diagnostics has lower revenue, but higher earnings than Quotient.
Analyst Ratings
This is a breakdown of current recommendations for Quotient and Cardio Diagnostics, as reported by MarketBeat.com.Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Quotient | 0 | 1 | 3 | 0 | 2.75 |
Cardio Diagnostics | 0 | 0 | 0 | 0 | N/A |
Quotient presently has a consensus target price of $60.00, suggesting a potential upside of 15,689.47%. Cardio Diagnostics has a consensus target price of $8.00, suggesting a potential upside of 566.72%. Given Quotient's higher possible upside, analysts clearly believe Quotient is more favorable than Cardio Diagnostics.
Institutional and Insider Ownership
77.3% of Cardio Diagnostics shares are owned by institutional investors. 10.5% of Quotient shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Quotient and Cardio Diagnostics' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Quotient | -413.55% | N/A | -88.21% |
Cardio Diagnostics | N/A | N/A | N/A |
About Quotient
(Get Rating)
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company also offers MosaiQ SDS Microarray that is designed as a serological disease screening microarray comprised assays to detect cytomegalovirus and Syphilis; MosaiQ MDS Microarray that is designed as a molecular disease screening microarray test for donor red cells or source plasma; MosaiQ IH Microarray as a blood grouping microarray; MosaiQ Autoimmune Microarray; MosaiQ COVID-19; and MosaiQ IH3 Microarray. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.
About Cardio Diagnostics
(Get Rating)
Cardio Diagnostics Holdings, Inc., a biotechnology company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks. The company was founded in 2017 and is headquartered in Chicago, Illinois.
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.
Quotient (NASDAQ:QTNT – Get Rating) and Cardio Diagnostics (NASDAQ:CDIO – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability and earnings.
納斯達克(QTNT-GET Rating)和卡迪奧診斷(納斯達克:CDIO-GET Rating)都是小盤醫療公司,但哪一家更好?我們將根據這兩家公司的風險、估值、分析師建議、股息、機構所有權、盈利能力和收益的強弱對其進行比較。
Valuation & Earnings
估值與收益
This table compares Quotient and Cardio Diagnostics' top-line revenue, earnings per share (EPS) and valuation.
此表比較了Quotent和Cardio Diagnostics的營收、每股收益(EPS)和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Quotient | $38.51 million | 0.03 | -$125.13 million | ($53.21) | -0.01 |
Cardio Diagnostics | N/A | N/A | -$140,000.00 | N/A | N/A |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
商 | 3,851萬美元 | 0.03 | -1.2513億美元 | ($53.21) | -0.01 |
心臟診斷學 | 不適用 | 不適用 | -$140,000.00 | 不適用 | 不適用 |
Cardio Diagnostics has lower revenue, but higher earnings than Quotient.
心臟診斷公司的收入低於商數,但收益高於商數。
Analyst Ratings
分析師評級
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Quotient | 0 | 1 | 3 | 0 | 2.75 |
Cardio Diagnostics | 0 | 0 | 0 | 0 | N/A |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
商 | 0 | 1 | 3 | 0 | 2.75 |
心臟診斷學 | 0 | 0 | 0 | 0 | 不適用 |
Quotient presently has a consensus target price of $60.00, suggesting a potential upside of 15,689.47%. Cardio Diagnostics has a consensus target price of $8.00, suggesting a potential upside of 566.72%. Given Quotient's higher possible upside, analysts clearly believe Quotient is more favorable than Cardio Diagnostics.
Qutient目前的共識目標價為60.00美元,暗示潛在上行空間為15,689.47%。心臟診斷公司的共識目標價為8.00美元,暗示潛在上漲566.72%。考慮到Quantient更有可能的上行空間,分析師們顯然認為Quantient比Cardio Diagnostics更有利。
Institutional and Insider Ownership
機構和內部人持股
77.3% of Cardio Diagnostics shares are owned by institutional investors. 10.5% of Quotient shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Cardio Diagnostics 77.3%的股份由機構投資者持有。Quantient 10.5%的股份由公司內部人士持有。強大的機構持股表明,捐贈基金、大型基金經理和對衝基金相信,從長期來看,一隻股票的表現將好於大盤。
Profitability
盈利能力
This table compares Quotient and Cardio Diagnostics' net margins, return on equity and return on assets.
此表比較了Quantient和Cardio Diagnostics的淨利潤率、股本回報率和資產回報率。
Net Margins | Return on Equity | Return on Assets | |
Quotient | -413.55% | N/A | -88.21% |
Cardio Diagnostics | N/A | N/A | N/A |
淨利潤率 | 股本回報率 | 資產回報率 | |
商 | -413.55% | 不適用 | -88.21% |
心臟診斷學 | 不適用 | 不適用 | 不適用 |
About Quotient
關於商
(Get Rating)
(獲取評級)
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company also offers MosaiQ SDS Microarray that is designed as a serological disease screening microarray comprised assays to detect cytomegalovirus and Syphilis; MosaiQ MDS Microarray that is designed as a molecular disease screening microarray test for donor red cells or source plasma; MosaiQ IH Microarray as a blood grouping microarray; MosaiQ Autoimmune Microarray; MosaiQ COVID-19; and MosaiQ IH3 Microarray. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.
Qutient Limited是一家商業階段的診斷公司,為美國、法國、日本和國際上的全球輸血診斷市場開發、製造、商業化和銷售產品。該公司正在開發MOSAIQ,這是一個專有技術平臺,提供免疫血液學、血清學疾病篩查和分子疾病篩查測試。其用於血型鑑定的常規試劑產品包括用於鑑定血型抗原的抗血清產品;用於鑑定血型抗體的試劑紅細胞;用於日常質量保證測試的全血控制產品;以及用於支持血型鑑定的輔助產品。該公司還提供MOSAIQ SDS微陣列,它是作為血清學疾病篩查微陣列設計的,包括鉅細胞病毒和梅毒檢測方法;MOSAIQ MDS微陣列,設計為供者紅細胞或來源血漿的分子疾病篩查微陣列;MOSAIQ IH血型微陣列;MOSAIQ自身免疫微陣列;MOSAIQ新冠肺炎;和MOSAIQ IH3微陣列。它向醫院、捐獻者採集機構、獨立檢測實驗室、原始設備製造商以及血庫運營和其他診斷公司銷售產品。Qutient Limited成立於2007年,總部設在瑞士EYSINS。
About Cardio Diagnostics
關於Cardio診斷公司
(Get Rating)
(獲取評級)
Cardio Diagnostics Holdings, Inc., a biotechnology company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks. The company was founded in 2017 and is headquartered in Chicago, Illinois.
心臟診斷控股公司是一家生物技術公司,開發和商業化基於表觀遺傳學的心血管疾病臨牀測試。它提供Epi+Gen,這是一種為期三年的症狀性冠心病(CHD)風險評估測試,針對包括心臟病發作在內的CHD事件。該公司成立於2017年,總部位於伊利諾伊州芝加哥。
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.
接受《商報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收最新新聞和分析師對Quantient及相關公司評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧